New Treatment for LGS
What is Fintepla (Fenfluramine)?
FINTEPLA® is a prescription medicine used to treat seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older.
Watch an overview of Fintepla® for Lennox-Gastaut Syndrome
– Presented by Dr. Michael Chez
*This video was recorded in early 2022 at the request of the LGS Foundation to provide information to our family members about this medication. The Foundation does not endorse this or any product and is here only to provide information relevant to patient families. LGS is tough. Finding information on treating LGS doesn’t need to be.
Relevant Information About Fintepla®:
FDA approval of this medicine was based on data that demonstrated the efficacy of this medicine in the most difficult to treat seizure types seen in LGS, including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground with a high likelihood of injury.
The FDA approval was supported by safety and efficacy data from a global, randomized, placebo-controlled Phase 3 clinical trial in 263 patients with LGS (age 2-35 years). This clinical trial demonstrated that fenfluramine significantly reduced the frequency of drop seizures.
- 25% of those patients on this medicine experienced 50% or greater reduction in drop seizure frequency
- 18% of patients had a more than 50 to but less than 75% reduction in drop seizure frequency
- 6% of patients had a greater than 75% reduction in drop seizure frequency
This medicine has a mechanism of action different from and complementary to current seizure medications, and it can be used with no disruptions to current antiseizure regimens.
The common adverse reactions that occurred in patients treated with this medicine were diarrhea; decreased appetite; fatigue; somnolence; vomiting.
More information about medication access assistance to patients, caregivers, and their medical teams can be found at www.FINTEPLA.com.
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.